Crinetics reports Q2 net loss $115.6M; PDUFA for paltusotine on Sept 25, 2025

Crinetics Pharmaceuticals, Inc.

2025-Q2 EPS reported -$2.27 revenue$1,392,000

Revenue $1.0M (vs $0.4M in Q2 2024); net loss widened to $115.6M from $74.1M YoY.
Cash, cash equivalents & investments $1.2B as of June 30, 2025; expected runway into 2029.
Paltusotine NDA PDUFA target action date September 25, 2025 for acromegaly; EMA review expected H1 2026.
Upcoming Phase 3 starts in H2 2025 for paltusotine in carcinoid syndrome and atumelnant in CAH (adult and pediatric).
2025 cash used in operations guided at $340-370M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.